Practice
Managing attention-deficit/hyperactivity disorder
Daniel A. Gorman and Elia Abi-Jaoude
CMAJ October 15, 2013 185 (15) E739; DOI: https://doi.org/10.1503/cmaj.121826
Daniel A. Gorman
Department of Psychiatry (Gorman, Abi-Jaoude), University of Toronto; Department of Psychiatry (Gorman), The Hospital for Sick Children; Department of Psychiatry (Abi-Jaoude), University Health Network, Toronto, Ont.
MDElia Abi-Jaoude
Department of Psychiatry (Gorman, Abi-Jaoude), University of Toronto; Department of Psychiatry (Gorman), The Hospital for Sick Children; Department of Psychiatry (Abi-Jaoude), University Health Network, Toronto, Ont.
MD MScArticle Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Respond to this article
Managing attention-deficit/hyperactivity disorder
Daniel A. Gorman, Elia Abi-Jaoude
CMAJ Oct 2013, 185 (15) E739; DOI: 10.1503/cmaj.121826
Jump to section
- Article
- Before starting treatment for attention-deficit/hyperactivity disorder (ADHD), other potential causes for symptoms should be ruled out
- Nonpharmacological treatments can be effective and should generally be started first
- Pharmacotherapy may be appropriate for patients with severe impairment or with insufficient benefit from nonpharmacological treatments
- Medications for ADHD are generally safe and well tolerated but can have adverse effects and are associated with some small but serious risks
- Pharmacotherapy requires frequent monitoring and dose adjustments, especially during the initial titration phase
- Footnotes
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.